专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20180223257A1 METHOD FOR THE INDUCTION AND EXPANSION OF NATURAL KILLER CELLS DERIVED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS 审中-公开
公开(公告)号：US20180223257A1
公开(公告)日：2018-08-09
申请号：US15948619
申请日：2018-04-09
申请人： NKMAX Co., Ltd.
发明人： Kyung Mi Lee , Seon Ah Lim , Cassian Yee
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K2039/5158 , C12N2501/2302 , C12N2502/1114 , C12N2502/30
摘要： The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

12. 发明申请

US20180105793A1 DEVICE WITH MULTIPLE MICROENVIRONMENTS AND METHODS THEREOF 审中-公开
公开(公告)号：US20180105793A1
公开(公告)日：2018-04-19
申请号：US15730371
申请日：2017-10-11
申请人： Amit Pathak , Samila Nasrollahi , Bapi Sarker
发明人： Amit Pathak , Samila Nasrollahi , Bapi Sarker
IPC分类号： C12N5/00 , C12M3/00 , C12M3/06 , C12M1/12
CPC分类号： C12N5/0075 , C12M3/006 , C12M23/16 , C12M25/06 , C12N5/0068 , C12N2502/30 , C12N2521/00 , C12N2533/30
摘要： Among the various aspects of the present disclosure is the provision of a device with multiple microenvironments and methods of use and manufacture thereof. An aspect of the present disclosure provides for a device for evaluating cell invasion. Another aspect provided by the present disclosure includes a method of making a device for evaluating cell invasion. Another aspect to the present disclosure provides for a method of testing a drug in vitro. Another aspect of the present disclosure provides for a method of identifying targets.

13. 发明授权

US09938498B2 Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells 有权
公开(公告)号：US09938498B2
公开(公告)日：2018-04-10
申请号：US14399371
申请日：2013-05-07
申请人： NKMAX Co., Ltd.
发明人： Kyung Mi Lee , Seon Ah Lim , Cassian Yee
IPC分类号： C12N5/0783 , A61K35/17 , A61K39/00
CPC分类号： C12N5/0646 , A61K35/17 , A61K2039/5158 , C12N2501/2302 , C12N2502/1114 , C12N2502/30
摘要： The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

14. 发明申请

US20180094244A1 COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT 审中-公开
公开(公告)号：US20180094244A1
公开(公告)日：2018-04-05
申请号：US15551284
申请日：2016-02-18
申请人： Enlivex Therapeutics Ltd.
发明人： Shai NOVIK , Dror MEVORACH
IPC分类号： C12N5/0783 , A61K35/17 , A61P37/06
CPC分类号： C12N5/0638 , A01K67/0271 , A01K2227/105 , A01K2267/0331 , A61K35/00 , A61K35/17 , A61K2035/122 , A61K2035/124 , A61P37/06 , C12N2502/1114 , C12N2502/30 , C12N2510/00 , G01N33/6863 , Y02A50/411
摘要： Compositions disclosed herein, and methods of use thereof included those for inhibiting or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T-cell therapy, wherein the subjects are administered compositions including apoptotic cells or apoptotic cell supernatants. In certain instances compositions and methods of use thereof disclosed herein do not reduce the efficacy of the CAR T-cell cancer therapy. Disclosed herein are also compositions and methods of use thereof for decreasing or inhibiting cytokine production in a subject experiencing cytokine release syndrome or cytokine storm including administration of a composition including apoptotic cells or an apoptotic cell supernatant.

15. 发明申请

US20180066220A1 DEVICES FOR CELL CULTURE AND METHODS OF MAKING AND USING THE SAME 审中-公开
公开(公告)号：US20180066220A1
公开(公告)日：2018-03-08
申请号：US15697306
申请日：2017-09-06
申请人： Pulak Nath , Jen-Huang Huang
发明人： Pulak Nath , Jen-Huang Huang
IPC分类号： C12M3/06 , C12M1/00 , C12M1/12 , C12M3/00 , C12N5/071 , G01N33/50 , C12M1/42 , C12M1/34
CPC分类号： C12M23/16 , C12M21/08 , C12M23/26 , C12M25/10 , C12M25/14 , C12M29/10 , C12M33/12 , C12M35/04 , C12M35/08 , C12M41/40 , C12N5/0697 , C12N2502/095 , C12N2502/1305 , C12N2502/1323 , C12N2502/27 , C12N2502/28 , C12N2502/30 , C12N2521/00 , C12N2533/78 , G01N33/5032
摘要： Devices and systems for cell culture that include one or more hollow fibers or channels integrated into a chamber are provided. The hollow fibers or channels and/or the chamber are seeded with one or more cell types. Methods of co-culturing two or more cell types in the devices are also provided.

16. 发明授权

US09834750B2 Cell-to-cell communication without exchange of mediating diffusible factors or using any physical contact between cells 有权
公开(公告)号：US09834750B2
公开(公告)日：2017-12-05
申请号：US14764222
申请日：2014-01-29
申请人： Christopher B. Reid , Keith Norris , Taehoon Cho , Victor Chaban
发明人： Christopher B. Reid , Keith Norris , Taehoon Cho , Victor Chaban
IPC分类号： C12N5/0793 , G01N33/50
CPC分类号： C12N5/0619 , C12N2502/30 , G01N33/5002
摘要： The present invention departs from using traditional modes of cell-to-cell communication and concerns exerting influence on a first cell or cell population by bringing a second cell or cell population into proximity with the first cell population without the use of mediating diffusible factors. Cell to cell communications traditionally occur by way of a variety of mechanisms including, for example, by direct coupling through gap junctions using antigen presentation or using ligand receptor interactions.

17. 发明申请

US20170196951A1 POLYVALENT ANTI-TUMOR FIBROBLAST VACCINE 审中-公开
公开(公告)号：US20170196951A1
公开(公告)日：2017-07-13
申请号：US15231759
申请日：2016-08-08
申请人： Batu Biologics, Inc.
发明人： Samuel C. Wagner , Thomas E. Ichim , Amit N. Patel
IPC分类号： A61K39/00 , C12N5/077 , C12N15/85 , A61K35/33
CPC分类号： A61K39/0011 , A61K35/33 , A61K2039/515 , A61K2039/5152 , C12N5/0656 , C12N15/85 , C12N2501/23 , C12N2501/2301 , C12N2501/2306 , C12N2501/2333 , C12N2501/24 , C12N2501/25 , C12N2502/1157 , C12N2502/30
摘要： Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells.

18. 发明授权

US09675732B2 3D tissue-engineered bone marrow for personalized therapy and drug development 有权
公开(公告)号：US09675732B2
公开(公告)日：2017-06-13
申请号：US14942543
申请日：2015-11-16
申请人： Washington University
发明人： Abdel Kareem Azab , Pilar de la Puente
IPC分类号： C12N5/071 , A61L27/22 , G01N33/50 , C12N5/077 , C12N5/09 , A61L27/54 , A61L27/36 , A61L27/38
CPC分类号： A61L27/3834 , A61L27/225 , A61L27/3608 , A61L27/3804 , A61L27/3808 , A61L27/3847 , A61L27/54 , A61L2300/414 , A61L2300/418 , A61L2300/42 , A61L2300/426 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0669 , C12N5/0694 , C12N2502/30 , C12N2513/00 , C12N2533/56 , G01N33/5011 , G01N33/5082 , G01N33/5088
摘要： A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.

19. 发明申请

US20160144018A1 METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS 审中-公开
标题翻译：制备抗人毛细血管病毒抗原T细胞的方法
公开(公告)号：US20160144018A1
公开(公告)日：2016-05-26
申请号：US14905138
申请日：2014-07-14
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
发明人： Christian S. Hinrichs , Steven A. Rosenberg
IPC分类号： A61K39/12 , C12N7/00 , C12N5/0783
CPC分类号： A61K39/12 , A61K35/17 , A61K2039/5158 , A61K2039/572 , A61K2039/585 , C12N5/0636 , C12N5/0638 , C12N7/00 , C12N2501/2302 , C12N2502/30 , C12N2710/20011
摘要： Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
摘要翻译：公开了制备人乳头状瘤病毒（HPV）特异性T细胞的分离群体的方法，包括将HPV阳性肿瘤样品分成多个片段; 分别培养多个片段; 从培养的多个片段获得T细胞; 测试T细胞用于特异性自体HPV阳性肿瘤的识别; 选择显示特异性自体HPV阳性肿瘤识别的T细胞; 并扩大选定的T细胞数以产生用于过继细胞治疗的HPV特异性T细胞群体。还公开了使用T细胞治疗或预防癌症的相关方法。

20. 发明申请

US20150252331A1 METHOD FOR INDUCING FUSION OF DENDRITIC CELL WITH TUMOUR CELL 有权
标题翻译：用于诱导具有肿瘤细胞的细胞融合的方法
公开(公告)号：US20150252331A1
公开(公告)日：2015-09-10
申请号：US14426163
申请日：2013-03-07
申请人： Yongxiang Zhao
发明人： Xiaoling Lu , Yi Peng
IPC分类号： C12N5/16
CPC分类号： C12N5/16 , A61K39/0011 , A61K2039/5152 , A61K2039/5154 , C12N2500/50 , C12N2502/1121 , C12N2502/30
摘要： Disclosed in the present invention is a method for inducing the fusion of a dendritic cell with a tumour cell, in the fusion process, successively adding an amount of polyethylene glycol and collagen to induce cell fusion highly efficiently, wherein polyethylene glycol can make the lipid molecules of the plasma membrane at the contact point between the two cells disperse and recombine, and then the cells fuse due to the mutual affinity between the bilayer membranes at the interface of the two cells and the surface tension between each other. The collagen can retrench the cell membrane and repair the cell membrane after fusion, thereby forming stable fusion cells highly efficiently, so it is suitable for the production of specific biological products such as tumour vaccines and monoclonal antibodies etc.
摘要翻译：在本发明中公开了一种用于诱导树突状细胞与肿瘤细胞融合的方法，在融合过程中，依次加入一定量的聚乙二醇和胶原来高效诱导细胞融合，其中聚乙二醇可制成脂质分子在两个细胞之间的接触点处的质膜分散和重组，然后由于在两个电池的界面处的双层膜之间的相互亲和力和彼此之间的表面张力而使细胞融合。胶原蛋白可以缩短细胞膜并融合后修复细胞膜，从而高效形成稳定的融合细胞，适用于生产特定的生物制品，如肿瘤疫苗和单克隆抗体等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式